secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-212128
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio Q1 2026 net loss $5.1M; GBM mPFS improved 97% vs SOC; cash $21.9M
------------------------------------------------------------------------

- Net loss of $5.1M ($0.26/sh) vs $5.6M ($2.16/sh) in Q1 2025; cash $21.9M up from $11.9M.
- GBM Phase 1/2: median PFS 13.0 months (repeat dose) vs 6.6 SOC (+97%); mOS still climbing at 17.2+ months.
- INB-619 TCE platform progressing toward IND; initial animal data expected in 2026.
- Anticipated FDA guidance on GBM regulatory pathway in 2H26; updated mOS data at ASCO 2026.
- R&D expenses $2.6M (down from $3.0M) on lower INB-400 clinical activity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312526212128/0001193125-26-212128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312526212128/inab-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-212128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer